ENEDYM
25.8.2021 11:32:09 CEST | Business Wire | Press release
Enedym Inc. ( “Enedym”), the technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, announced today that it formed a partnership with the Napino Group. (“Napino”), one of India's leading suppliers of automotive electronic products. Under the terms of the partnership, Napino will license Enedym’s switched reluctance motor (SRM) technology for use in 2-wheel electric motorcycles and scooters in India.
Dr. Ali Emadi, Founder, President, and CEO of Enedym commented, “We are excited to announce this deal with Napino. The partnership between Enedym and Napino is transformative and significant given it will provide a more stable and secure global manufacturing supply chain, combined with sustainable next generation motor technology. The landscape of the automotive industry is changing rapidly and we are excited to provide next generation electric motor technology that aligns with the needs of leading OEMs. Through the use of Enedym’s SRMs – which eliminate the need for rare earth metals often sourced exclusively from China – we are providing a gateway to low cost/high quality manufacturing of next generation motors, inverters, and controllers.
Dr. Emadi added, “We are in the midst of a historic shift, both in terms of electrification, focus on sustainability, and the need for secure and stable supply chains. Partnering with Napino will allow us to supply our next generation motor technology within a massive market and offer Indian based and global OEM’s a viable manufacturing alternative to China.”
Mr. Vaibhav Raheja, Joint Managing Director of Napino commented, “We are extremely delighted to announce our partnership with Enedym. Achieving removal of magnets and rare earth elements in these products offers great advantages not only from a geo-political point of view, but also ensures sensible use of natural resources. We are confident that the affordable and robust solution being created by our engineering & manufacturing teams will offer quicker adoption of electric mobility in India. Our vision is to make India a global manufacturing hub for EV motors and contribute towards making it carbon neutral.”
Commenting on the partnership, Mr. Naveen Kumar, Group CEO of Napino, said; “Zero emission mobility has become a global movement & with Enedym as our partner, we are gearing up to meet the current & future requirements of electric mobility. As a technology driven organization, Napino has constantly reinforced its position as a leading Auto Electronics System Supplier, offering innovative, sustainable and robust solutions for its customers. Working on cutting-edge technologies ensures that we continue to be at the forefront of the rapidly transforming business landscape.”
Sumit Dhanuka, Founder & Managing Partner of Precog Innovation Partners, commented, "We are excited to have enabled this unique strategic partnership between Napino and Enedym. This collaboration brings together Enedym’s cutting-edge design and development capabilities in the SRM motor technology space and Napino’s strong automotive manufacturing and go-to-market strengths in the Indian market, helping us realize the shared vision towards Net-Zero Mobility and an Aatmanirbhar Bharat (Self-reliant India).”
Enedym recently announced a $15 million financing round from an international group of strategic investors within the U.S., Canada, Europe, and India.
About Enedym, Inc.
Enedym is a technology start-up company from McMaster University. The company is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 50 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair in Hybrid Powertrain Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. Enedym’s vision is to reduce the cost of electric propulsion motors significantly and power a new paradigm in the electric motor industry through novel switched reluctance motor (SRM) drive technologies. Enedym aspires to help save the planet, one electric motor market at a time. To learn more about Enedym, please visit www.enedym.com and our YouTube channel at Enedym YouTube .
Napino Auto & Electronics Ltd
Napino is one of India's leading supplier of automotive electronic products. It employs roughly 6000 employees. The portfolio includes ECUs, capacitor-discharge ignitor, regulator rectifier, wiring harness, handlebar switches, and E Mobility products among other electronic offerings. As a leader in its segment with complete design, development, and manufacturing capabilities, Napino offers innovative solutions to major automobile manufacturers. Through its robust R&D capabilities and sustainable partnerships with global players, Napino aspires to lead technology innovation in automotive electronics. To learn more, please visit http://napino.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom